Aucentra Therapeutics Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
2
- Latest Deal Type
-
Series A
- (Cancelled)
- Investors
-
2
Aucentra Therapeutics General Information
Description
Developer of therapeutic drug candidates designed to advance targeted treatment for severe cancers. The company offers a deep pipeline of proprietary targeted anti-cancer drugs including candidates for the treatment of leukemia, breast cancer, colorectal cancer, glioblastoma, lung cancer, prostate cancer, and ovarian cancer, it develops breakthrough classes of drugs to address unmet medical needs for some of the most severe cancers, enabling healthcare providers and research institutions to access addressing critical unmet medical needs.
Contact Information
Website
www.aucentra.comCorporate Office
- L7, UniSA Bradley Building Institute
- North Terrace
- Adelaide, South Australia 5000
- Australia
Corporate Office
- L7, UniSA Bradley Building Institute
- North Terrace
- Adelaide, South Australia 5000
- Australia
Aucentra Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series A) | 08-May-2023 | Cancelled | Clinical Trials - Phase 1 | |||
| 2. Grant | 14-Dec-2021 | Completed | Clinical Trials - Phase 1 | |||
| 1. Early Stage VC | 01-Feb-2021 | Completed | Startup |
Aucentra Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Aucentra Therapeutics Patents
Aucentra Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023901679-A0 | Inhibitors of protein kinases for use as anti-proliferative agents | Pending | 29-May-2023 | ||
| AU-2022901432-A0 | Inhibitors of protein kinases for use as anti-proliferative agents | Pending | 27-May-2022 | ||
| AU-2022901195-A0 | Inhibitors for use in therapy | Pending | 05-May-2022 | ||
| AU-2022900659-A0 | Use of 4-thiazol-n-(pyridin-2-yl)pyrimidin-2-amine derivatives in combination therapies for cancer | Pending | 17-Mar-2022 | ||
| AU-2023236039-A1 | Use of 4-thiazol-n-(pyridin-2-yl)pyrimidin-2-amine derivatives in combination therapies for cancer | Pending | 17-Mar-2022 | A61K31/506 |
Aucentra Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Aucentra Therapeutics Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| South Australian Department for Innovation and Skills | Government | |||
| UniSA Ventures | University | Minority |
Aucentra Therapeutics FAQs
-
When was Aucentra Therapeutics founded?
Aucentra Therapeutics was founded in 2017.
-
Where is Aucentra Therapeutics headquartered?
Aucentra Therapeutics is headquartered in Adelaide, Australia.
-
What is the size of Aucentra Therapeutics?
Aucentra Therapeutics has 2 total employees.
-
What industry is Aucentra Therapeutics in?
Aucentra Therapeutics’s primary industry is Drug Discovery.
-
Is Aucentra Therapeutics a private or public company?
Aucentra Therapeutics is a Private company.
-
What is Aucentra Therapeutics’s current revenue?
The current revenue for Aucentra Therapeutics is .
-
Who are Aucentra Therapeutics’s investors?
South Australian Department for Innovation and Skills and UniSA Ventures have invested in Aucentra Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
